Sign In
Buy RPTX
$2.65
+0 (+0%)
At Close: Apr 24, 2026
RPTX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Repare Therapeutics Inc. is Fair to Shareholders
10:59pm, Friday, 14'th Nov 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Repare Therapeutics Inc. (NASDAQ: RPTX) to XenoTherapeutics, Inc. is fair to Repare share
MILWAUKEE , Nov. 14, 2025 /PRNewswire/ -- The Ademi Firm is investigating Repare (Nasdaq: RPTX) for possible breaches of fiduciary duty and other violations of law in its recently announced transactio
Repare Therapeutics Inc. (RPTX) Reports Break-Even Earnings for Q3
07:01pm, Friday, 14'th Nov 2025
Repare Therapeutics Inc. (RPTX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.81 per share a year ago.
Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc.
04:44pm, Friday, 14'th Nov 2025
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that it has ente
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced it will share in
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates
09:10am, Friday, 08'th Aug 2025
Repare Therapeutics Inc. (RPTX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.82 per share a year ago.
Repare (RPTX) Q2 Loss Narrows 52%
07:13am, Friday, 08'th Aug 2025
Repare (RPTX) Q2 Loss Narrows 52%
Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
07:00am, Friday, 08'th Aug 2025
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today reported financial results
Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib
04:05pm, Tuesday, 15'th Jul 2025
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced it has entered i
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results
04:05pm, Tuesday, 13'th May 2025
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today reported financial results
Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025
01:00pm, Friday, 25'th Apr 2025
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the acce
Repare Therapeutics Announces Leadership Transitions
04:39pm, Monday, 31'st Mar 2025
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that Ste
What Makes Repare Therapeutics (RPTX) a New Buy Stock
01:00pm, Tuesday, 11'th Mar 2025
Repare Therapeutics (RPTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 07'th Mar 2025
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results
07:05am, Monday, 03'rd Mar 2025
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results.
